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Abstract
Background: Bronchiectasis is defined as a permanent dilation of the airways arising from chronic
bronchial inflammation/infection. In 50% of cases, no etiology can be identified. Recently, the role
of the epithelial sodium channel ENaC has been pointed out in the pathophysiology of cystic
fibrosis, a disease due to mutations in the CFTR gene and causing bronchiectasis in the airways.
Moreover, it was found that transgenic mice overexpressing ENaCβ present cystic fibrosis-like lung
disease symptoms. Our aim was to evaluate if a defective ENaC protein could be involved in the
development of bronchiectasis.
Methods:  We extensively analysed ENaCβ  and  γ  genes in 55 patients with idiopathic
bronchiectasis and without two mutations in the coding regions of CFTR. Thirty-eight patients
presented functional abnormalities suggesting impaired sodium transport (abnormal sweat chloride
concentration or nasal potential difference measurement), and 17 had no such evidence.
Results: Sequencing of the exons and flanking introns of the ENaCβ and γ gene identified five
different amino-acid changes (p.Ser82Cys, p.Pro369Thr, p.Asn288Ser in ENaCβ ; and p.Gly183Ser,
p.Glu197Lys in ENaCγ) in heterozygous state in 8 patients. The p.Ser82Cys amino-acid change was
found in 3 unrelated patients who were also heterozygous for a CFTR mutation or variant (1
p.F508del, 1 IVS8-5T, and 1 IVS8-5T:1716G>A (p.E528E)). The other mutations were found in
patients without CFTR mutation, the p.Glu197Lys mutation in 2 patients and the other variants in
single patients. Among the 8 patients bearing an ENaC mutation, 5 had functional abnormalities
suggesting impaired sodium transport.
Conclusion: Our results suggest that several variants in ENaCβ and γ genes might be deleterious
for ENaC function and lead to bronchiectasis, especially in patients who are trans-heterozygotes
for ENaCβ/CFTR mutations or variants.
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Background
Bronchiectasis is an abnormal dilation of bronchi due to
the destruction of their walls. The main symptoms associ-
ated with bronchiectasis are chronic cough, purulent spu-
tum and recurrent lower respiratory tract infections, and
most patients show a varying degree of airflow obstruc-
tion. In approximately 50% of cases, causative factors are
identified such as childhood infection, immune defects,
allergic bronchopulmonary aspergillosis, aspiration of
irritants, cystic fibrosis, primary ciliary dyskinesia, rheu-
matoid arthritis, other connective tissue disorders, ulcera-
tive colitis, and alpha-1 antitrypsin deficiency. The
remaining 50% of cases without identified etiology are
classified as idiopathic [1].
The amiloride-sensitive epithelial sodium channel
(ENaC) allows passive transport of sodium into the cells.
It is expressed in epithelial cells lining the renal tubule,
the respiratory airways and alveoli, the distal colon and
the duct of several exocrine glands, such as salivary and
sweat glands. ENaC is composed of three subunits (alpha,
beta and gamma) in the proposed stoichiometry 2α :1β
:1γ, or 3α :3β :3γ [2,3]. Each ENaC subunit activity may be
regulated by other proteins such as CFTR (Cystic Fibrosis
Transmembrane conductance Regulator) which is the pro-
tein involved in cystic fibrosis [4]. Human clinical disor-
ders due to ENaC  mutations are a rare occurrence.
However, they have been well described. Liddle's syn-
drome (OMIM 177200), an autosomal dominant form of
volume-expanded low-renin hypertension is caused by
gain-of-function mutations in the β or γ ENaC subunits
[5]. In contrast, loss-of-function mutations in the α, β or γ
ENaC subunits have been found in autosomal recessive
pseudohypoaldosteronisme type I (PHA-I) (OMIM
264350) with salt wasting, hyperkalemia and metabolic
acidosis [6]. In PHA-I patients, there is also a defective
sodium transport in the sweat glands that causes elevated
sweat chloride and sodium concentrations. Hence, as
sweat testing is the standard diagnostic test for cystic fibro-
sis, PHA-I is a classic differential diagnosis of elevated
sweat chloride concentration, although usually readily
distinguishable from cystic fibrosis.
Recently, the ENaC channel has been shown to play a crit-
ical role in lung and airway mice physiology : ENaCα
knock-out mice died shortly after birth of respiratory fail-
ure due to an inability to clear fluid from the alveolar
space [7]. Moreover, mice overexpressing ENaCβ subunit,
but not α or γ, developed cystic-fibrosis-like disease with
mucus obstruction and poor bacterial clearance [8]. In
humans, cystic fibrosis disease in the airways is linked to
the combined defects of failure to secrete chloride and of
accelerated sodium transport resulting from the absence
of ENaC inhibition by the defective CFTR protein [9].
Moreover, some respiratory abnormalities have been
reported in patients with clinical disorders due to ENaC
mutations. Hence, in Liddle's syndrome, an increased
sodium channel activity in the nasal epithelium was
observed [10]. In PHA-I, patients frequently exhibit respi-
ratory tract disease, especially up to the age of 5–6 years
[11] and in some patients, a defect in nasal epithelial
sodium transport has been described with an excess of air-
way surface liquid [12].
Recently, sequencing of the exons and flanking introns of
the genes encoding the α, β, and γ subunits of ENaC in
twenty non-classic CF patients, that is patients with bron-
chiectasis and elevated sweat chloride concentrations but
without two CFTR mutations, identified in four patients
five missense mutations (one in ENaCα  and four in
ENaCβ) and one splicing mutation in the 3' splice site of
ENaCβ intron 12 [13]. Our aim was to evaluate if a defec-
tive ENaC protein could be involved in the development
of bronchiectasis. To do so, we extensively analysed
ENaCβ and ENaCγ genes in 55 patients with idiopathic
bronchiectasis and identified 8 patients bearing one
mutation in the ENaCβ or γ genes. One mutation was
found in 3 unrelated patients who were also heterozygous
for a CFTR mutation or variant. Moreover, 5 patients bear-
ing one mutation in the ENaCβ or γ genes had functional
abnormalities in the nasal epithelium or in the sweat
glands suggesting impaired sodium transport.
Material and Patients
Patients and controls
We studied 55 patients (13 men and 42 women) with dif-
fuse idiopathic bronchiectasis recruited from the respira-
tory physiology department of Cochin University
Hospital, Paris, France. Bronchiectasis was diagnosed on
chronic cough with purulent sputum and bronchial dila-
tion involving more than one lobe on high-resolution
computed tomography scanning [14]. A complete
genomic screening for CFTR gene mutations by denatur-
ing high performance liquid chromatography (DHPLC)
and direct sequencing analysis was performed and no
patient carried two pathogenic CFTR mutations. No other
known etiology of bronchiectasis was found such as infec-
tious causes, immune disorders, primary ciliary dyski-
nesia or chronic rheumatic inflammatory conditions as
assessed by : complete medical history, blood investiga-
tions (serum protein electrophoresis, immunoglobulins
(Ig), IgG subclasses, Aspergillus fumigatus radioallergosorb-
ent (RAST), autoantibodies including rheumatoid factor,
α1-antitrypsin) and nasal mucociliary clearance (meas-
ured by the saccharin test and nasal nitric oxide measure-
ment). No patient had a history of salt wasting or a
familial history of respiratory or metabolic diseases, and
all patients were normotensive.Respiratory Research 2008, 9:46 http://respiratory-research.com/content/9/1/46
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Sweat test and nasal PD measurements were performed
on the 55 patients in order to study sodium transport in
the sweat glands and in the nasal epithelium. Nasal PD
measurements were performed by using 2 silver/silver
chloride electrodes connected to a high impedance volt-
meter, one electrode being in contact with the inferior sur-
face of the nasal inferior turbinate and the other, with the
subcutaneous tissue of the forearm [15]. The basal nasal
PD reflects the basal rate of nasal sodium absorption [15].
Group 1 (38 patients) was defined as patients who had
either abnormal sweat chloride concentration (13
patients) of more than 40 mmol per liter in a sample of at
least 75 mg of sweat induced by means of pilocarpine ion-
tophoresis [16] or abnormal basal nasal PD (> |-30| mV
in 14 patients or < |-10| mV in 11 patients) measured as
described by Knowles et al. [15]. When the basal nasal PD
was above |-30| mV, a pharmacological study was per-
formed as described by Knowles et al. [15]. This pharma-
cological study allows to explore each component of nasal
epithelial ion transport by using various pharmacological
agents such as amiloride, a blocker of epithelial sodium
channel, a low chloride solution which allows the deter-
mination of basal chloride conductance and isoprotere-
nol which explores CFTR-related chloride transport [15].
Group 2 (17 patients) included patients with no evidence
of impaired sodium transport as evaluated by normal
sweat chloride concentrations (< 40 mmol/L) and normal
basal PD (≥ |-10| and ≤ |-30| mV). Values of forced expir-
atory volume in 1 second (FEV1) and forced vital capacity
(FVC) were determined on the day of nasal PD measure-
ments and expressed as percentages of predicted values.
A control group comprising 50 subjects of Caucasian ori-
gin with no pulmonary disease were studied for the CFTR
and ENaC genes. All individuals gave written informed
consent.
Methods
Genomic DNA was extracted from peripheral blood lym-
phocytes according to standard protocols and was used to
amplify the thirteen exons (twelve coding exons; exon 2 to
exon 13) and the flanking sequences of the ENaCβ and
ENaCγ  genes. Because lung-specific overexpression of
ENaCα was not associated with raised Na+ transport rates
or lung disease in mouse [8], we did not study this subu-
nit. All samples were collected after a written informed
consent was obtained.
The human ENaCβ and ENaCγ genes are located on chro-
mosome 16, composed of thirteen exons and encode a
640 and 649 aminoacid protein, respectively. The ATG
start codon is located in exon 2 and the TGA stop codon
is located in exon 13. The coding regions of ENaCβ and
ENaCγ have been amplified in twelve fragments. Primer
sequences have been previously described [17]. Reactions
were performed in a volume of 50 μl containing 50 mM
Tris-HCl (pH 8.4), 1.5 mM MgCL2, 200 μM of all four
deoxynucleotides, 0.5 mM each of the primers, 2.5 units
of Taq Polymerase (Gold, Perkin Elmer) and 100 ng tem-
plate DNA. Forty cycles were then performed with dena-
turation for 30 sec at 72°C. The DNA synthesis step of the
final cycle was extended to 7 min. For DHPLC analysis,
the amplified DNA was heated at 94°C for 7 min, and at
55°C for 4 min to favour formation of heteroduplexes.
Mutation analysis of the patients with idiopathic bron-
chiectasis was performed by using DHPLC (Wave DNA
fragment analysis system, DNAsep column; Transgenom-
ics). DHPLC conditions were chosen according to the
Wavemaker program (Transgenomics, Santa Clara, CA,
USA) as previously described [17]. PCR products were
subjected to chromatography using appropriate tempera-
tures and acetonitrile gradient at a flow rate of 0.9 ml/mn,
and those showing an abnormal DHPLC profile were
directly sequenced on an automated sequencer (ABI 3100,
Applied Biosystems, USA) using the BigDye Terminator
method (Figure 1).
The influence of base substitutions on putative exonic
splice element (ESE) sites was determined with the ESE-
finder program [18].
Statistics
The Hardy-Weinberg equation tested allelic disequilib-
rium for the common polymorphisms. Comparison
between subjects grouped on the basis of their pheno-
types was accomplished by Fisher's exact test (two tailed)
for categorical variables and by Mann-Whitney U test for
continuous variables. P values below 0.05 were defined as
significant.
Results
Patients
All patients were caucasian europeans except for 4
patients who originated from Africa (2 patients), Asia (1
patient) and South America (1 patient). Table 1 shows the
clinical characteristics of the patients. In both groups,
some patients carried one CFTR mutation or variant : in
Group 1, 5 patients were heterozygous for the p.F508del,
1 for the 2183AA>G mutation, 1 for the 4375-20G>A var-
iant, 2 for the IVS8-5T allele and 3 for the c.1716G>A
(p.E528E) variant. In Group 2, 2 patients were hetero-
zygous for the p.F508del, 2 for the p.R117H-7T mutation,
3 for the IVS8-5T allele, and 1 for the c.1717G>A
(p.E528E) variant. There was no statistical difference in
the frequencies of CFTR mutations between the 2 groups.
Screening of the ENaC gene
All the exons and exon-intron junctions of the ENaCβ and
ENaCγ gene were screened for mutations and/or polymor-
phisms by DHPLC in the 55 patients with bronchiectasisRespiratory Research 2008, 9:46 http://respiratory-research.com/content/9/1/46
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of unknown origin. DHPLC analysis revealed the absence
of mutations or polymorphisms in exons 3, 4, 6, 9, 10, 11,
12 of the ENaCβ gene and in exons 2, 5, 6, 7, 8 and 12 of
the ENaCγ gene.
Mutations in the ENaCβ gene
Screening of the ENaCβ  gene by DHPLC and direct
sequencing revealed three different amino-acid changes :
p.Ser82Cys c.245C>G in exon 2, p.Asn288Ser c.863A>G
in exon 5 and p.Pro369Thr c.1105C>A in exon 7 (Figure
(A) Denaturing high performance liquid chromatography patterns of polymerase chain reaction products corresponding to  exon 5 and 7 of ENaC beta : DHPLC profile corresponding to normal exon sequence (control), and altered DHPLC because of  a substitution Figure 1
(A) Denaturing high performance liquid chromatography patterns of polymerase chain reaction products corresponding to 
exon 5 and 7 of ENaCβ : DHPLC profile corresponding to normal exon sequence (control), and altered DHPLC because of a 
substitution. (B) Fluorescence sequence analysis of exon 5 and exon 7 of the ENaCβ gene, using the forward primer. Arrows 
indicate position of the p.Asn288Ser and p.Pro369Thr mutations in exon 5 and 7, respectively.
Table 1: Main characteristics of the 55 patients with idiopathic bonchiectasis
Variable Group 1 (n = 38) Group 2 (n = 17) P value
Age (years) 54 ± 3 52 ± 4 NS
BMI (Kg.m-2)2 3  ±  1 2 0  ±  1 N S
FEV1 (% predicted) 86 ± 4 75 ± 6 NS
Sweat chloride (mmol/L) 34 ± 3 22 ± 2 0.03
Basal nasal PD (mV) -23 ± 2  -18 ± 1  NS 
Results are expressed as mean ± SEM; BMI : body mass index, FEV1 : forced expiratory volume in 1 second, PD : potential difference.Respiratory Research 2008, 9:46 http://respiratory-research.com/content/9/1/46
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1). The p.Ser82Cys amino-acid change has been previ-
ously described [13] and was found in 3 unrelated
patients. The two other mutations have not been previ-
ously described and were found each in one patient. The
amino acids Ser82 and Asn288 are completely conserved
in paralogues in human, canis, rabbit, rat and mouse.
However, the amino acid Pro369 is not completely con-
served in paralogues (Ala in mouse and rat) [19].
Characteristics of the patients bearing mutations in the 
ENaCβ gene
These three missense mutations were identified 4 times in
patients from Group 1 (2 : p.Ser82Cys, 1 : p.Pro369Thr
and 1 : p.Asn288Ser; 4/38; 10.5%) and only once in
patients from Group 2 (p.Ser82Cys; 1/17; 5.9%). None of
these mutations were found in the ethnically-matched
control group. Interestingly, the 3 patients bearing the
p.Ser82Cys mutation were also heterozygous for a CFTR
mutation or variant (1 p.F508del, 1 IVS8-5T, and 1 IVS8-
5T:1716G>A (p.E528E)).
The main characteristics of the patients bearing a missense
mutation in ENaCβ gene are shown in Table 2. All were
caucasian europeans, except a 35-year old female who
originated from South America. Most of them were quite
elderly adults (≥ 60 years-old), all of them had a normal
or subnormal respiratory function. None had a bronchial
colonization by Pseudomonas aeruginosa. In patients from
group 1, all but one had a normal or a very low basal nasal
PD and a pharmacological study was not performed. The
only patient with a high basal nasal PD in absolute value
(- 43 mV) bore the mutation p.Pro369Thr. In this patient,
the sweat chloride concentration was normal (22 mmol/
L) and the PD response to pharmacological solutions was
normal : it was reduced to – 22 mV with amiloride, a
sodium channel inhibitor. A normal response was
observed after perfusion of a low chloride solution (- 44
mV) and subsequently after perfusion of the β-agonist iso-
proterenol which induces cAMP dependent chloride con-
ductance (- 56 mV), showing a functional CFTR protein.
Polymorphisms in the ENaCβ gene
Four silent polymorphisms (p.Pro93Pro c.279C>T in
exon 2; p.Phe293Phe c.879C>T in exon 5; p.Pro407Pro in
exon 8; and p.Asn629Asn in exon 13) and one nucleotide
change in the noncoding region (c.IVS12-17C>T) were
also found. The silent polymorphism p.Phe293Phe was
observed in six unrelated patients (6/55; 11%) (6 in group
1 (15%) vs 0 in Group 2 (0%)) and the common poly-
morphism p.Pro93Pro was identified at the heterozygous
state in 18 patients (18/55; 33%) (13 in Group 1 and 5 in
Group 2) and at the homozygous state in 9 patients (9/55;
16%) (5 in Group 1 (13%) and 4 in Group 2 (23%)). The
two other silent polymorphisms (p.Pro407Pro and
p.Asn629Asn) were only observed once.
Mutations in the ENaCγ gene
Screening of the ENaCγgene by DHPLC and direct
sequencing revealed two amino-acid changes
(p.Gly183Ser c.547G>A in exon 3 and p.Glu197Lys
c.591G>A in exon 3).
Characteristics of the patients bearing mutations in the 
ENaCγ gene
The p.Gly183Ser amino-acid change was found in a
female patient from Group 1 who originated from Africa
and the p.Glu197Lys amino-acid change was found in
two unrelated patients from Group 2. None of these
mutations were found in the ethnically-matched control
group.
The main characteristics of the patients bearing a missense
mutation in ENaCγgene are shown in Table 3. None car-
ried a CFTR mutation. The patient from Group 1 carrying
the p.Gly183Ser mutation had normal sweat chloride
concentrations (7 mmol/L), an abnormal basal nasal PD
(- 39 mV) with normal response to amiloride (- 29 mV)
and to low chloride solution (- 40 mV). No response was
observed after perfusion with isoprenaline (- 40 mV). In
Group 2, the 2 patients carrying the p.Glu197Lys were
among the most severely affected patients of Group 2 with
airway obstruction on pulmonary function tests.
Polymorphisms in the ENaCγ gene
Six silent polymorphisms (p.Tyr129Tyr c.387T>C in exon
3; p.Ser145Ser c.435C>T in exon 3; p.Ileu158Ileu
c.474T>C in exon 3; p.Gly183Gly c.549C>T in exon 3;
p.Ser212Ser c.636C>T in exon 4; p.Val492Val c.1476A>G
in exon 12; p.Leu649Leu c.1947 C>G in exon 13) and five
intronic sequence variations (c.IVS7+14A>G;
Table 2: Main characteristics of the 5 patients with idiopathic bonchiectasis bearing a missense mutation in ENaCβ gene
Age (years) Sex BMI (Kg.m-2) FEV1 (%pred.) CFTR mutation ENaCβ mutation Sweat Cl- (mmol/L) Basal PD (mV)
Group 1 66 F 22 77 IVS8-5T p.Ser82Cys 44 - 13
62 F 19 89 F508del p.Ser82Cys 38 - 8
35 F 23 86 none p.Pro369Thr 22 - 43
60 F 21 93 none p.Asn288Ser 57 - 10
Group 2 67 M 20 80 IVS8-5T p.Ser82Cys 28 - 22
F : female, M : male, BMI : body mass index, FEV1 : forced expiratory volume in 1 second, pred : predicted, PD : nasal potential difference.Respiratory Research 2008, 9:46 http://respiratory-research.com/content/9/1/46
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IVS7+69A>G; c.1371+29T>C; c.1432-7G>A; c.1432-
106A>G) were also found. The common polymorphisms
p.Tyr129Tyr and p.Ileu158Ileu (also named rs4365290
and rs5735, respectively) were observed in 28 patients
(28/55 i.e. 51%; 18 (47%) in Group 1 and 10 (59%) in
Group 2) at the heterozygous state. In the ensembl data-
base which provides accurate analysis of the current
human genome data [20], these variants were observed at
the heterozygous state in 54%. The common polymor-
phism p.Leu649Leu (also named rs5723) was identified
in 18 patients (18/55 i.e. 33%; 12 (32%) in Group 1 and
6 (35%) in Group 2) and was in perfect linkage with the
two intronic sequence variations c.1371+29T>C and
c.1432-7G>A. The common polymorphism p.Ser212Ser
(also named rs16977041) was only observed in two unre-
lated patients from Group 1 (2/55; 4%) and the two other
silent mutations p.Ser145Ser and p.Val492Val were only
observed once (both from Group 1; 2%). None of the
intronic nucleotide changes altered the consensus splice
sites, suggesting that they are common polymorphisms
rather than disease-causing mutations.
Discussion
Our study shows that, out of 55 patients with bronchiecta-
sis of unknown origin, 8 patients carried at least one mis-
sense mutation in ENaCβ or ENaCγ genes. Interestingly,
the p.Ser82Pro mutation was found in 3 patients hetero-
zygous for a CFTR mutation or variant. Functional tests to
investigate the rate of sodium transport in the sweat
glands or in the nasal epithelium were not contributive in
suspecting the presence of these mutations since 3
patients out of the 8 patients bearing one ENaC mutation
had a normal sweat test and a normal basal PD. However,
in the 5 patients with abnormal functional tests bearing
one ENaC mutation, the effect of the mutation on ENaC
function might be hypothesized.
Liddle's syndrome is caused by nonsense, and frameshift
mutations resulting mostly in truncation of carboxyl ter-
mini of β and γsubunits, and by missense mutations pri-
marily located in a conserved PY motif (PPPXYXXL motif,
codon 611 to 623). This leads to defective regulation of
ENaC expression and activity, and gain-of-function
[5,21]. PHA-I is mostly caused by nonsense, splice and
frameshift mutations in the ENaCα, β and γgenes which
produce truncated nonfunctional proteins, or missense
mutations in the ENaCα and β genes that decrease ENaC
trafficking to the cell surface. All these mutations cause
loss-of-function of the ENaC protein and were reported in
patients with a severe phenotype of PHA-I [22]. In con-
trast, out of 22 mutations causing PHA-I, only 3 were mis-
sense mutations and they were reported in PHA-I patients
with a mild form of the disease [22]. While the non-mis-
sense mutations lead to absence of normal-length protein,
missense mutations allow the synthesis of a normal-
length subunit that is more likely to support a residual
channel activity. In this study, 55 patients with bron-
chiectasis of unknown origin have been examined for
mutations in coding regions of the ENaCβ and γ genes
and 5 different missense mutations were identified. It can
by hypothesized that the missense mutation resulting
from the nucleotide substitution allowed normal sodium
reabsorption in the kydneys (therefore avoiding the syn-
dromes of pseudohypoaldosteronism or pseudoaldos-
teronism seen in PHA-I and Liddle's syndrome); but this
missense mutation might mildly affect ENaC function in
the airway epithelium, and this abnormal ENaC protein
would modify the extent of sodium absorption and lead
to airway disease and bronchiectasis.
Four of the missense mutations were detected in patients
with functional abnormalities suggesting impaired
sodium transport in the sweat glands or in the nasal epi-
thelium : two variants (p.Pro369Thr, p.Asn288Ser in
ENaCβ) were detected in this study for the first time and
the other two (p.Ser82Cys and p.Gly183Ser) have been
described before [13]. These variants have not been previ-
ously found in normal subjects in several studies [22-24]
and were not detected in our ethnically-matched control
group and in a "control" population of 56 cystic fibrosis
patients with two pathogenic CFTR mutations [17]. They
are therefore unlikely to be common polymorphisms.
These variants were each found at the heterozygous state
and the deleterious effect of this finding might be ques-
tioned.  In vitro studies in the Xenopus laevis oocyte
expression system could be performed to evaluate the pre-
cise effect of the new mutations we have found on ENaC
structure and function. However, we did not performe
these studies because it is thought that this system is not
sensitive enough to detect little changes in ENaC activity
and that only mutations leading to large changes in ENaC
activity are liable to be detected [25]. Moreover, it is not
Table 3: Main characteristics of the 3 patients with idiopathic bronchiectasis bearing a missense mutation in ENaCγ gene
Age (years) Sex BMI (Kg.m-2) FEV1 (%pred.) CFTR mutation ENaCγ mutation Sweat Cl(mmol/L) Basal PD (mV)
Group 1 36 F 20 90 none p.Gly183Ser 7 - 39
Group 2 24 F 19 64 none p.Glu197Lys 11 - 17
46 M 22 35 none p.Glu197Lys 17 - 18
F : female, M : male, BMI : body mass index, FEV1 : forced expiratory volume in 1 second, pred : predicted, PD : nasal potential difference.Respiratory Research 2008, 9:46 http://respiratory-research.com/content/9/1/46
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known whether amphibian cells such as Xenopus oocytes
possess the whole cellular machinery involved in the com-
plex regulation of the ENaC in mammalian cells [26].
However, the functional abnormalities found in the
patients speak for a role of the ENaC mutation in the
pathophysiology of their airway disease. Hence, the
patients bearing the p.Pro369Thr and p.Gly183Ser muta-
tions had normal sweat chloride concentration (22 and 7
mmol/L, respectively) and a high basal PD (- 43 and - 39
mV, respectively) showing elevated nasal sodium trans-
port. This pattern is similar to that described in Liddle's
syndrome [10]. Indeed, in the presence of ENaC gain-of-
function mutations such as in Liddle's syndrome, the
sodium and chloride reabsorption in the sweat duct are
normal leading to normal sweat chloride concentrations.
In contrast, there is an increased sodium reabsorption in
the airway epithelium causing an increased nasal PD.
Therefore, the functional pattern we observed for sodium
transport in the sweat gland and in the airway epithelium
suggests that p.Pro369Thr and p.Gly183Ser are mutations
causing a gain of ENaC function. As for the patient bear-
ing the p.Asn288Ser mutation, she had high sweat chlo-
ride concentration (57 mmol/L) with low basal nasal PD
(- 10 mV), displaying the pattern described for PHA-I
patients [12]. In loss-of-function mutations in the ENaC
gene as seen in PHA patients, the defective ENaC causes
defective sodium and chloride reabsorption in the sweat
duct and elevated sweat chloride and sodium concentra-
tions. In the airways, the low sodium reabsorption leads
to a low basal nasal PD. Therefore, the functional pattern
we observed for the p.Asn288Ser mutation suggests it to
be a loss-of-function mutation.
The p.Ser82Cys mutation was relatively common in our
population (3/55; 5.4%) and was found in both groups,
with or without functional abnormalities suggesting
impaired sodium transport. The two patients from Group
1 bearing the p.Ser82Cys mutation had rather high sweat
chloride concentrations (44 and 38 mmol/L) with rather
low basal nasal PD (- 13 and - 8 mV), displaying the pat-
tern described for PHA-I patients [12], that is patients
bearing ENaC mutations causing a loss of function in the
ENaC channel. However, this p.Ser82Cys mutation has
been reported at a frequency of 2% in control subjects,
thus making its mere presence deleterious doubtful [27].
Interestingly, the three patients bearing this variant also
bore one CFTR mutation (p.F508del in one case) or one
CFTR  variant (IVS8-5T in one patient, and IVS8-5T-
1716G>A in the other), which was not the case for the
four patients bearing one other ENaC  mutation. This
p.Ser82Cys variant was not found in our cohort of 56
cystic fibrosis patients bearing two pathogenic CFTR
mutations [17]. To date, a combination of one ENaC
mutation, including this p.Ser82Cys mutation, plus a
CFTR  mutation, has been occasionally reported in
patients with idiopathic bronchiectasis [27]. Here, we
have identified three patients with bronchiectasis who are
trans-heterozygotes for ENaCβ/CFTR mutations or vari-
ants, and these cases strongly suggest an interaction
between different susceptibility factors in the pathogene-
sis of their airway disease. As it has been previously sug-
gested in sporadic cases of PHA-I with various
polymorphisms identified in the ENaC  gene [21], this
sporadic presentation of bronchiectasis with trans-hetero-
zygotie for ENaCβ/CFTR mutations could be the result of
digenic or multigenic expression and complex hereditary
transmission.
Among the 8 patients bearing one missense mutation in
ENaCβ γ gene, 3 had functional tests suggesting normal
sodium transport in the sweat glands and in the nasal epi-
thelium. This, together with the heterozygous state of the
ENaC mutation, may suggest that this mutation does not
play a role in the pathophysiology of these patients' air-
way disease. However, as one of the patient bore also one
CFTR variant (IVS8-5T) and as the other two bore the
same ENaCγ mutation (p.Glu197Lys) and were among
the most affected patients of the group, the implication of
the  ENaC  mutation can not be ruled out. If the last
hypothesis is true, our results indicate that the functional
tests studying sodium transport, such as sweat testing and
nasal PD, are not always contributive in suspecting a
mutation in the ENaC gene. Moreover, it strengthens our
hypothesis that airway disease related to partly defective
ENaC protein might be the result of complex susceptibil-
ity factors and this is all the more emphasized by the
growing knowledge of all the accessory factors regulating
ENaC [28].
In a group of 55 patients with idiopathic bronchiectasis,
we identified 8 patients bearing one mutation in the
ENaCβ or γ genes. Although the significance of these find-
ings at the functional level requires further investigation,
a defective ENaC protein may be involved in some
patients with idiopathic bronchiectasis or cystic fibrosis-
like lung disease with only one CFTR mutation identified.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
IF, DH and TB designed the study, MV and SS performed
the genetic analysis, IF performed the nasal PD measure-
ments. All authors have participated in the analyses of
data. IF and TB had the major responsibility for drafting
the manuscript. All authors read and approved the final
manuscript.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Respiratory Research 2008, 9:46 http://respiratory-research.com/content/9/1/46
Page 8 of 8
(page number not for citation purposes)
Aknowledgements
The authors are indebted to Prof. M. Aubier (Bichat Hos-
pital, Paris), Dr L. Bassinet (Centre Hospitalier Intercom-
munal de Créteil), Dr P.R. Burgel (Cochin Hospital,
Paris), Prof J. Cadranel (Tenon Hospital, Paris), Prof. L.J.
Couderc (Foch Hospital, Suresnes), Prof. B. Crestani
(Bichat Hospital, Paris), Dr N. Dufeu (Cochin Hospital,
Paris), Prof. D. Dusser (Cochin Hospital, Paris), Dr I.
Honoré (Centre Hospitalier Intercommunal de Créteil),
Dr J. Lacronique (Cochin Hospital, Paris), Dr E. Rivaud
(Foch Hospital, Suresnes) for referring the patients. This
work was supported by a grant from the association Vain-
cre la Mucoviscidose.
References
1. Pasteur MC, Helliwell SM, Houghton SJ, Webb SC, Foreraker JE,
Coulden RA, Flower CD, Bilton D, Keogan MT: An investigation
into causative factors in patients with bronchiectasis.  Am J
Respir Crit Care Med 2000, 162:1277-1284.
2. Eskandari S, Snyder PM, Kreman M, Zampighi GA, Welsh MJ, Wright
EM: Number of subunits comprising the epithelial sodium
channel.  J Biol Chem 1999, 274:27281-27286.
3. Anantharam A, Palmer LG: Determination of epithelial Na+
channel subunit stoichiometry from single-channel conduct-
ances.  J Gen Physiol 2007, 130:55-70.
4. Stutts MJ, Rossier BC, Boucher RC: Cystic fibrosis transmem-
brane conductance regulator inverts protein kinase A-medi-
ated regulation of epithelial sodium channel single channel
kinetics.  J Biol Chem 1997, 272:14037-14040.
5. Hansson JH, Schild L, Lu Y, Wilson TA, Gautschi I, Shimkets R, Nel-
son-Williams C, Rossier BC, Lifton RP: A de novo missense muta-
tion of the b subunit of the epithelial sodium channel causes
hypertension and Liddle syndrome, identifying a proline-rich
segment critical for regulation of channel activity.  Proc Natl
Acad Sci USA 1995, 92:11495-11499.
6. Chang SS, Grunder S, Hanukoglu A, Roster A, Mathew PM, Hanu-
koglu I, Schild L, Lu Y, Shimkets RA, Nelson-Williams C, Rossier BC,
Lifton RP: Mutations in subunits of the epithelial sodium chan-
nel cause salt wasting with hyperkaliemic conditions acido-
sis, pseudohypoaldosteronism type 1.  Nat Genet 1996,
12:248-253.
7. Hummler E, Barker P, Gatzy J, Beermann F, Verdumo C, Schmidt A,
Boucher R, Rossier BC: Early death due to defective neonatal
lung liquid clearance in αENaC-deficient mice.  Nat Genet 1996,
12:325-328.
8. Mall M, Grubb BR, Harkema JR, O'Neal WK, Boucher RC: Increased
airway epithelial Na+ absorption produces cystic fibrosis-like
lung disease in mice.  Nature Med 2004, 10:487-493.
9. Boucher RC: New concepts of the pathogenesis of cystic fibro-
sis lung disease.  Eur Respir J 2004, 2(1):146-158.
10. Baker E, Jeunemaitre X, Portal AJ, Grimbert P, Markandu N, Persu A,
Corvol P, MacGregor G: Abnormalities of nasal potential differ-
ence measurements in Liddle's syndrome.  J Clin Invest 1998,
102:10-14.
11. Hanukoglu A, Bistritzer T, Rakover Y, Mandelberg A: Pseudohy-
poaldosteronism with increased sweat and saliva electrolyte
values and frequent lower respiratory tract infections mim-
icking cystic fibrosis.  J Pediatr 1994, 125:752-755.
12. Kerem E, Bistritzer T, Hanukoglu A, Hofmann T, Zhou Z, Bennett W,
MacLaughlin E, Barker P, Nash M, Quittel L, Boucher R, Knowles MR:
Pulmonary epithelial sodium-channel dysfunction and excess
airway liquid in pseudohypoaldosteronism.  N Engl J Med 1999,
341:156-162.
13. Sheridan MB, Fong P, Groman JD, Conrad C, Flume P, Diaz R, Harris
C, Knowles M, Cutting GR: Mutations in the beta subunit of the
epithelial Na+ channel in patients with a cystic fibrosis-like
syndrome.  Hum Mol Genet 2005, 14:3493-3498.
14. McGuinness G, Naidich DP: CT of airway disease and bron-
chiectasis.  Radiol Clin North Am 2002, 40:1-19.
15. Knowles MR, Paradiso AM, Boucher RC: In vivo nasal potential
difference: techniques and protocols for assessing efficacy of
gene transfer in cystic fibrosis.   Hum Gene Ther 1995,
6(4):445-455.
16. LeGrys VA, Yankaskas JR, Quittell LM, Marshall BC, Mogayzei PJ:
Diagnostic sweat testing : the cystic fibrosis foundation
guidelines.  J Pediatr 2007, 151:85-89.
17. Viel M, Leroy C, Hubert D, Fajac I, Bienvenu T: ENaCβ and γ genes
as modifier genes in cystic fibrosis.  J Cyst Fibros 2008, 7:23-29.
18. Website title   [http://rulai.cshl.org]
19. Website title   [http://genome.ucsc.edu]
20. Website title   [http://www.ensembl.org]
21. Furuhashi M, Kitamura K, Adachi M, Niyoshi T, Wakida N, Ura N,
Shikano Y, Shinshi Y, Sakamoto K, Hayashi M, Satoh N, Nishitani T,
Tmita K, Shinamoto K: Liddle's syndrome caused by a novel
mutation in the proline-rich PY motif of the epithelial
sodium channel beta-unit.  J Clin Endocrinol Metab 2005,
90:340-344.
22. Edelheit O, Hanukoglu I, Gizewska M, Kandemir N, Tenenbaum-Rak-
over Y, Yurdakok M, Zajaczek S, Hanukoglu A: Novel mutations in
epithelial sodium channel (ENaC) subunit genes and pheno-
typic expression of multisystem pseudohypoaldos-
teronism.   Clin Endocrinol (Oxf) 2005, 62(5):547-553.
23. Arai K, Zachman K, Shibasaki T, Chrousos GP: Polymorphisms of
amiloride-sensitive sodium channel subunits in five sporadic
cases of pseudohypoaldosteronism: Do they have pathologic
potential?  J Clin Endocrinol Metab 1999, 84:2434-2437.
24. Saxena A, Hanukoglu I, Saxena D, Thompson RJ, Gardiner RM, Hanu-
koglu A: Novel mutations responsible for autosomal recessive
multisystem pseudohypoaldosteronism and sequence vari-
ants in epithelial sodium channel α-, β-, and γ-subunits genes.
J Clin Endocrinol Metab 2002, 87:3344-3350.
25. Hannila-Handelberg T, Kontula K, Tikkanen I, Tikkanen T, Fyhrquist
F, Helin K, Fodstad H, Piippo K, Miettinen HE, Virtamo J, Krusius T,
Sarna S, Gautschi I, Schild L, Hiltunen TP: Common variants of the
beta and gamma subunits of the epithelial sodium channel
and their relation to plasma renin and aldosterone levels in
essential hypertension.  BMC Med Genet 2005, 20:1-13.
26. Persu A, Barbry P, Bassilana F, Houot AM, Mengual R, Lazdunski M,
Corvol P, Jeunemaitre X: Genetic analysis of the beta subunit of
the epithelial Na+ channel in essential hypertension.  Hyper-
tension 1998, 32:129-37.
27. Ak A, Jaspers M, Radojkovic D, Nuytten H, Rauh R, Korbmacher C,
Dupont L, De Boeck C, Hjalte L, De Monestrol I, Cassiman J, Cup-
pens H: The involvment of ENaC in CF patients in whom a
mutation cannot be identified on both CFTR genes
[abstract].  Pediatr Pulmonol 2005, 40(suppl 28):174.
28. Warnock DG: Accessory factors and the regulation of epithe-
lial sodium channel activity.  J Clin Invest 1999, 103:593.